Bone Biologics (BBLG) Liabilities and Shareholders Equity (2012 - 2026)

Bone Biologics (BBLG) has reported Liabilities and Shareholders Equity for 14 consecutive years, with $5.8 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 50.11% year-over-year to $5.8 million; the TTM figure through Dec 2025 stood at $22.3 million (up 49.14% YoY), while the FY2025 annual figure was $5.8 million, up 50.11% from the prior year.
• Liabilities and Shareholders Equity eased to $5.8 million in Q4 2025 per BBLG's latest filing, from $6.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $8.5 million in Q4 2022 and bottomed at $4438.0 in Q2 2021.
• Historically, Liabilities and Shareholders Equity has averaged $4.6 million across 5 years, with a median of $5.1 million in 2022.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 127409.71% — and 2024, when it plunged 58.11%.
• Bone Biologics' Liabilities and Shareholders Equity stood at $6.7 million in 2021, then advanced by 27.26% to $8.5 million in 2022, then tumbled by 56.0% to $3.7 million in 2023, then gained by 3.31% to $3.9 million in 2024, then jumped by 50.11% to $5.8 million in 2025.
• Business Quant data shows BBLG's Liabilities and Shareholders Equity at $5.8 million in Q4 2025, $6.4 million in Q3 2025, and $7.0 million in Q2 2025.